search for


Characterization of JAK2 V617F (1849 G > T) Mutation in Cervical Cancer Related to Human Papillomavirus and Sexually Transmitted Infections
Journal of Cancer Prevention 2018;23:82-6
Published online June 30, 2018
© 2018 Korean Society of Cancer Prevention.

Masoumeh Abdolmaleki1, and Amir Sohrabi2

1Department of Biology, East Tehran Branch, Islamic Azad University, Tehran, Iran, 2Department of Molecular Biology, Research Center of Health Reference Laboratory, Ministry of Health and Medical Education, Tehran, Iran
Correspondence to: Amir Sohrabi, Department of Molecular Biology, Research Center of Health Reference Laboratory, Ministry of Health and Medical Education, 48 Keykhosro Shahrokh Alley, Zartoshtian Alley, Hafez Avenue, P.O. Box: 1131636111, Tehran, Iran, Tel: +98-2166728112 (Ext.114), Fax: +98-2166728121, E-mail:, ORCID: Amir Sohrabi,
Received March 21, 2018; Revised May 27, 2018; Accepted June 7, 2018.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Human papillomavirus (HPV) genotypes that infect the genital tract play a main etiologic role in cervical cancer progression. Other environmental factors, such as sexually transmitted diseases and the host genetic pattern, contribute to infection persistence of the uterus and cervical epithelium in sustaining their malignancy. The Janus kinase 2 is a non-receptor tyrosine kinase in cell signaling process of tumor genesis. In the present study, JAK2 V167F mutation was distinguished in women with sexually transmitted infections, such as Herpes simplex virus 2, Chlamydia trachomatis and Mycoplasma genitalium and cervical cancer.


This case-control survey was performed on 195 liquid based cytology of women specimens. Fifty, 98, and 47 samples were from women with known cervical cancer, HPV positive and HPV negative, respectively. Single nucleotide polymorphism analysis, sexually transmitted infections detection and HPV genotyping were carried out using approved PCR- RFLP, in-house multiplex TaqMan Real Time PCR and the reverse dot blot hybridization assay.


HPVs 6, 16, 18, 11, 31, and 51 were the most common genotypes. The prevalence rate of multiple HPV genotypes was 46.0% to 10.1%. Analysis of JAK2 V617F (1849 G > T) showed that prevalence of mutation was GG (65.1%), GA (34.9%), and TT (0%), respectively. There were no statistically significant differences between this mutation and variables of population survey (P ≥ 0.05).


The molecular epidemiology study on the genetic polymorphisms, i.e., JAK2 V617F and other single nucleotide polymorphisms as a diagnostic tool is necessary for cancer screening and prophylactic programs.

Keywords : Human papillomavirus, Sexually transmitted infections, Janus kinase 2, Polymorphism, Cervical cancer, Iran

Cervical cancer is ranked second across the top five women malignancies in worldwide. Multiple factors, such as human papillomavirus (HPV) and sexually transmitted infections (STIs) followed by the activity of oncogenes and environmental factors, are linked to complex diseases like cervical precancerous and cancerous.1,2 Persistent high risk HPV genotypes with other genital pathogens are essential for enhancing the susceptibility to genital malignancies.37

Some potential cancer antigens and biomarkers, such as CA-125, CA-19-9, epigenetic and genetic alterations and polymorphisms in tumor suppressor genes are utilized in prognostic and diagnostic exposures in clinical management of women.811

It seems that 50% to 90% of early cervical neoplasia items regress spontaneously, although host genetic factors especially the immune system plays an important role in preventing genital disorders.1214 The single nucleotide polymorphisms in immune modulating genes like JAK-STAT pathway are associated with a variety of cancers. STAT activation needs tyrosine phosphorylation by a receptor associated Janus kinase (JAK). JAKs particularly JAK2 are non-receptor tyrosine kinase that plays a significant role in cell signaling process of tumor genesis. Genital co-infections are simultaneously proposed to increase susceptibility to cervical cancer.1418

In the present molecular epidemiology survey, the most common sexually transmitted pathogens, e.g., Chlamydia trachomatis, HSV-2 and Mycoplasma genitalium and HPV as major agent of cervical malignancies were investigated in women with and at risk for cervical cancer. The JAK2 V617F (1849 G > T) mutation was selected based on the scientific databases which polymorphism is evaluated for probability of association with cervical cancer related to these STIs in Iranian subjects.


1. Study population

A total of 195 liquid based cytology (LBCs) specimens were collected from women referred to Mohebe-Yas Hospital and private pathobiology laboratories, Tehran, Iran. Cervical scrapping and genital lesions with known cervical cancer (all the diagnoses were confirmed by histopathology examinations), HPV positive and healthy women (as negative control) were 50, 98, and 47, respectively. In order to meet ethical considerations, each cancer patient was informed about the objectives of study and signed a consent form before participating in the study. Other samples were archival specimens and necessary clinical data were recorded from medical documents. The LBCs were transported to the Reference Health Laboratory, Tehran, Iran in a proper storage area where they were stored at −20°C until experimental phase.

2. Statistical analysis

In order to determine any significant relationship, an independent test (chi-square) was used between the variables C. trachomatis, HSV-2 and M. genitalium and HPV genotypes with cervical cancer and existence of JAK2 V617F (1849 G > T) polymorphism. A statistical test was performed at the significant level of 0.05 using IBM SPSS software ver. 23 (IBM Co., Armonk, NY, USA).

3. Genome extraction

Microbial and genomic DNA from LBCs specimens was extracted using the QIAamp DNA Mini kit (QIAGEN, Hilden, Germany) according to the manufacturer’s instructions.19

4. Human papillomavirus genotyping

HPV detection and genotyping was performed by a reverse dot blot hybridization diagnostic kit using INNO-LiPA® HPV Genotyping Extra I&II (Fujirebio, Tokyo, Japan), according to the previously described method.19

5. Analysis of JAK2 V617F (1849 G > T) polymorphism

Genome was analyzed by qualitative PCR and RFLP using gene specific primers. PCR amplification was carried out in a 25 μL reaction volume containing 2× master mix red 1.5 mM MgCl2 (Ampliqon, Odense, Denmark), 10 pmol/μL of forward and reverse primer and 10 μL of the extracted DNA as template. This reaction mixture was amplified at 94°C for 5 minutes and for 40 cycles in a thermal cycler (Techne, Staffordshire, UK) under the following conditions: 94°C for 45 seconds, 60°C for 45 seconds, 72°C for 50 seconds, plus a final extension step at 72°C for 10 minutes. Each experiment was performed with distilled water as a negative PCR control and patients with known genome as positive control. In RFLP analysis, 10 μL of JAK2 PCR product was digested with 20 μL restriction enzyme reaction containing 16 μL sterile distilled water, 3 μL enzyme buffer and Bsax1 (2,000 U/μL) enzyme (New England Biolabs®, Ipswich, MA, USA). The PCR-RFLP products were separated by electrophoresis on a 3% agarose gel, stained by Sybr safe (Invitrogen, Carlsbad, CA, USA), and were visualized under ultraviolet light along with a molecular weight marker (50 bp). In a JAK2 V617F (1849 G > T) PCR-RFLP reaction was expected to produce 364 bp as undigest, 161 and 203 bp as wild type, 364, 203, 161 bp as heterozygous and 364 bp as homozygous.20

6. Qualitative TaqMan Real Time PCR Detection of sexually transmitted infections

We developed primers and probes for C. trachomatis, HSV-2 and M. genitalium detection in TaqMan Real Time PCR reaction. The method data were described in previously document.19


In 148 out of 195 LBCs specimens, HPV s were detected for 28 HPV genotypes. HPVs 6 (35.13%), 16 (32.43%), 18 (21.62%), 11 (9.46%), 31 (9.46%), and 51 (9.46%) were the most common genotypes. The prevalence rate of multiple HPV genotypes was 46.0% to 10.1%. The mean age of subjects was 35.5 ± 10.13 years with the age range of 19 to 70 years. The high HPV prevalence was observed in 25 to 35 years of age groups (32.8 %). The STIs outcomes detection using TaqMan Real Time PCR was 3 (1.54%) for M. genitalium, 24 (12.3%) for C. trachomatis and 1(0.5%) for HSV-2. The details data of HPV genotyping and STIs aren’t shown.19 The genotype distribution for JAK2 V617F (1849 G > T) polymorphism in women with cervical cancer, HPV positive and HPV negative groups are shown in Table 1. JAK2 genotype TT was not distinguished in all of subjects, although prevalence of the GG genotype was 127 (65.1%) in case and control groups. The observed genotype frequencies among the STIs pathogens are summarized in Table 2. No significant difference was observed in genotype frequency between patients (cervical cancer, HPV positive and healthy women) for JAK2 polymorphism and STI pathogens (P ≥ 0.05).


HPV genotypes are certainly the major causes of genital malignancies particularly cervical cancer and precancerous lesions. There is growing evidence of HPV being a relevant factor in other anogenital cancers as well as head and neck cancers.2123 The annual incidence of cervical cancer related to high risk-HPV genotypes in Iran is closed to 947 cases and mortality rate is 370 in 3.1 million women at risk for cervical cancer (female population aged ≥ 15 years).24 Epigenetic and genetic polymorphisms patterns as diagnostic biomarker and HPV genotypes detection can be used for determining appropriate treatment strategy for early stages of cervical cancer and increase survival in cervical carcinogenesis.9,25 Persistent high risk-HPV genotypes with other STIs, environmental and host genetic factors may play critical roles in further malignant conversion of cervical epithelium and genital areas.

Analysis of JAK2 V617F (1849 G > T) polymorphism gene was assessed in women with and at risk for cervical cancer and genital disorders that only a few studies have been reported in the literature. Our results showed that the TT genotype was not detected in any study groups. The GG genotype was commonly observed in HPV negative women. Although, the highest rate of the GT genotype was recognized in women suffering from cervical cancer who were coinfected with HPVs and C. trachomatis. The SPSS ver. 23 statistical analysis showed that no significant difference was observed in 1849 G > T genotype frequency and STIs between the study population (P ≥ 0.05). The acquired mutation JAK2 V617F has been described in the majority of patients with hematologic disorders. This mutation is characterized by a G to T transverse at nucleotide 1849 in exon 12 of the JAK2 gene, located on the chromosome 9p, leading to substitution of valine to phenylalanine at amino acid position 617 in JAK2 protein. The JAK-STAT pathway is a critical tyrosine kinase modulating immune responses. However, the implication of JAK2 mutation in infectious disorders remains undetermined. Although in clinical therapeutic exposure, there is the potential of infectious complications in JAK inhibitors as JAK2 V617F kinase. The activating mutation V617F of JAK2 has been identified as one of the hallmarks in the pathogenesis of malignancies.1517,20,26 We have not found any evidence for existence of HSV-2 and M. genitalium in cancer patients. It appears that C. trachomatis is more prevalent than HSV-2 and M. Genitalium in Iran. As a result, all of cancer patients infected with HPV genotypes may be affected on these STIs. This concern should be evaluated in further studies.

The controversies in population surveys may be due to differences in the sample size, specimen’s management, the genetic patterns and the assay. The results from of single nucleotide polymorphisms may be influenced by unapproved molecular assays, primer combinations, home-brew methods and multiple infections which have been effective on sensitivity and specificity of diagnostic expousers.2730

In further epidemiological studies, whole genome and targeted sequencing of the JAK2 mutation exon 12 would be the best way for finding any correlation between the SNPs and other environmental and infection factors. Recent molecular efforts led to increased use of genetic biomarkers in diagnostic laboratories and in the surveillance system of cancers. These can be helpful for selecting the appropriate prevention strategies especially in early stage of neoplasia.


We are grateful and indebted to reference health laboratory staffs and Dr. Akram Sadat Tabatabaei-Panah (assistant professor of Biology Department, East Tehran Branch, Islamic Azad University, Tehran, Iran).


No potential conflicts of interest were disclosed.


Distribution of JAK2 V617F poymorphism in women with STIs and cervical cancer

Population studyWomen with cervical cancer (50 cases)Women without cervical cancer (145 cases)TotalTest of independence
Patients categorizesCIN I = 9 cases; CIN II = 6; CIN III = 35HPV positive (98 cases); HPV negative (47 cases)
STIs prevalence7 PositiveaUndetectedUndetected721101028
JAK2 V617F (1849 G > T)Wild type10061191018χ2 = 0.232 (chi-square & Fisher’s exact test)
Homozygous0000000000(P >0.05)b

STI, sexually transmitted infection; HPV, human papillomavirus; CT, Chlamydia trachomatis; MG, Mycoplasma genitalium.

aCT positive cases includes: CIN = 1, CIN II = 1 and CIN 3 = 5.

bThere was no significant difference.

Frequency of JAK2 polymorphism in participants

Clinical subjectJAK2 V617F (1849 G > T)

Wild typeHeterozygousHomozygous
Women without cervical cancer (145 cases)
 HPV positive (98 cases)72 (73.5)26 (26.5)0
 HPV negative (47 cases)33 (70.2)14 (29.8)0
Women with cervical cancer (50 cases)22 (44.0)28 (26.5)0 (0)
 CIN I (9 cases)450
 CIN II (6 cases)240
 CIN III (35 cases)16190
Total127 (65.1)68 (34.9)0 (0)

Values are presented as number (%) or number only. HPV, human papillomavirus.

  1. Husain, RS, and Ramakrishnan, V (2015). Global variation of human papillomavirus genotypes and selected genes involved in cervical malignancies. Ann Glob Health. 81, 675-83.
  2. Mboumba-Bouassa, RS, Prazuck, T, Lethu, T, Meye, JF, and B챕lec, L (2017). Cervical cancer in sub-Saharan Africa: an emerging and preventable disease associated with oncogenic human papillomavirus. Med Sante Trop. 27, 16-22.
  3. Shi, N, Lu, Q, Zhang, J, Li, L, Zhang, J, and Zhang, F (2017). Analysis of risk factors for persistent infection of asymptomatic women with high-risk human papilloma virus. Hum Vaccin Immunother. 13, 1-7.
    Pubmed KoreaMed CrossRef
  4. Mittal, S, Basu, P, Muwonge, R, Banerjee, D, Ghosh, I, and Sengupta, MM (2017). Risk of high-grade precancerous lesions and invasive cancers in high-risk HPV-positive women with normal cervix or CIN 1 at baseline-A population-based cohort study. Int J Cancer. 140, 1850-9.
    Pubmed CrossRef
  5. Shayanfar, N, Hosseini, N, Panahi, M, Azadmanesh, K, Mohammadpour, M, and Kadivar, M (2013). Detection of mucosal type human papillomavirus in cutaneous squamous cell carcinoma in Iran. Pathol Res Pract. 209, 90-4.
  6. Shayanfar, N, Babaheidarian, P, Rahmani, H, Azadmanesh, K, Sohrabi, A, and Mohammadpour, M (2012). Epidermodysplasia verruciformis associated with plasmablastic lymphoma and hepatitis B virus infection. Acta Dermatovenerol Croat. 20, 267-71.
  7. Sohrabi, A, Mirab-Samiee, S, Modarresi, MH, Izadimood, N, Azadmanesh, K, and Rahnamaye-Farzami, M (2014). Development of in-house multiplex real time PCR for human papillomavirus genotyping in Iranian women with cervical cancer and cervical intraepithelial neoplasia. Asian Pac J Cancer Prev. 15, 6257-61.
    Pubmed CrossRef
  8. Yasa, C, Takmaz, O, Dural, O, and Akhan, SE (2013). The value of tumor markers in endometrial carcinoma: review of literature. J Cancer Ther. 4, 966-70.
  9. Sohrabi, A, Mirab-Samiee, S, Rahnamaye-Farzami, M, Rafizadeh, M, Akhavan, S, and Hashemi-Bahremani, M (2014). C13orf18 and C1orf166 (MULAN) DNA genes methylation are not associated with cervical cancer and precancerous lesions of human papillomavirus genotypes in Iranian women. Asian Pac J Cancer Prev. 15, 6745-8.
    Pubmed CrossRef
  10. Zhang, W, Wang, L, and Xin, Z (2018). Combination of serum CA19-9 and CA125 levels and contrast-enhanced ultrasound parametric data facilitates to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer. Medicine (Baltimore). 97, e0358.
  11. Hwang, SJ, and Shroyer, KR (2012). Biomarkers of cervical dysplasia and carcinoma. J Oncol. 2012, 507286.
  12. Sohrabi, A, Hajia, M, Jamali, F, and Kharazi, F (2017). Is incidence of multiple HPV genotypes rising in genital infections?. J Infect Public Health. 10, 730-3.
    Pubmed CrossRef
  13. Sohrabi, A, Farzami, MR, Samiee, MH, and Modarresi, MH (2015). An overview on papillomaviruses as the main cause of cervical cancer. Iran J Obstet Gynecol Infertil. 18, 14-25.
  14. Barra, F, Lorusso, D, Leone Roberti Maggiore, U, Ditto, A, Bogani, G, and Raspagliesi, F (2017). Investigational drugs for the treatment of cervical cancer. Expert Opin Investig Drugs. 26, 389-402.
    Pubmed CrossRef
  15. Vaclavicek, A, Bermejo, JL, Schmutzler, RK, Sutter, C, Wappenschmidt, B, and Meindl, A (2007). Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer. Endocr Relat Cancer. 14, 267-77.
    Pubmed CrossRef
  16. Zhao, D, Pan, C, Sun, J, Gilbert, C, Drews-Elger, K, and Azzam, DJ (2015). VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to up regulate Myc and Sox2. Oncogene. 34, 3107-19.
  17. Zhang, RR, Wang, H, Hui, N, and Zhang, P (2013). Enhanced antitumor effect of axitinib synergistic interaction with AG490 via VEGFR2/JAK2/STAT3 signaling mediated epithelial-mesenchymal transition in cervical cancer in vitro. Asian Biomed. 7, 39-49.
  18. Zhang, Z, Fye, S, Borecki, IB, and Rader, JS (2014). Polymorphisms in immune mediators associate with risk of cervical cancer. Gynecol Oncol. 135, 69-73.
    Pubmed KoreaMed CrossRef
  19. Moharreri, M, and Sohrabi, A (2018). Herpes simplex virus 2, Mycoplasma genitalium and Chlamydia trachomatis: are they related to HPV genotypes associated with cervical cancer and genital infections?.
  20. Mervat, MMA, Ola, AH, and Mervat, SHA (2015). Detection of JAK2 mutation in cases of myelodysplastic syndrome. Zagazig Univ Med J. 21, 79-86.
  21. Dijkstra, MG, Snijders, PJ, Arbyn, M, Rijkaart, DC, Berkhof, J, and Meijer, CJ (2014). Cervical cancer screening: on the way to a shift from cytology to full molecular screening. Ann Oncol. 25, 927-35.
    Pubmed CrossRef
  22. Nunobiki, O, Ueda, M, Toji, E, Yamamoto, M, Akashi, K, and Sato, N (2011). Genetic polymorphism of cancer susceptibility genes and HPV infection in cervical carcinogenesis. Patholog Res Int. 2011, 364069.
    Pubmed KoreaMed
  23. Suh, DH, Kim, M, Kim, K, Kim, HJ, Lee, KH, and Kim, JW (2017). Major clinical research advances in gynecologic cancer in 2016: 10-year special edition. J Gynecol Oncol. 28, e45.
    Pubmed KoreaMed CrossRef
  24. Bruni, L, Barrionuevo-Rosas, L, Albero, G, Serrano, B, Mena, M, and G처mez, D (). ICO Information Centre on HPV and Cancer (HPV Information Centre)
  25. Botezatu, A, Socolov, D, Iancu, IV, Huica, I, Plesa, A, and Ungureanu, C (2013). Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and promoter methylation in cervical oncogenic lesions and cancer. J Cell Mol Med. 17, 543-49.
    Pubmed KoreaMed CrossRef
  26. Pe챰a, G, Cai, B, Deitch, EA, and Ulloa, L (2010). JAK2 inhibition prevents innate immune responses and rescues animals from sepsis. J Mol Med (Berl). 88, 851-9.
  27. Sohrabi, A, Rahnamaye-Farzami, M, Mirab-Samiee, S, Mahdavi, S, and Babaei, M (2016). Comparison of in-house multiplex real time PCR, Diagcor GenoFlow HPV array test and INNO-LiPA HPV genotyping extra assays with LCD- array kit for human papillomavirus genotyping in cervical liquid based cytology specimens and genital lesions in Tehran, Iran. Clin Lab. 62, 615-9.
  28. Arbyn, M, Ronco, G, Cuzick, J, Wentzensen, N, and Castle, PE (2009). How to evaluate emerging technologies in cervical cancer screening?. Int J Cancer. 125, 2489-96.
    Pubmed KoreaMed CrossRef
  29. Sohrabi, A, and Hajia, M (2017). Cervical cancer and genital infections: assessment of performance and validation in human papillomavirus genotyping assays in Iran, its neighbouring countries and Persian gulf area. Iran J Pathol. 12, 35-44.
    Pubmed KoreaMed
  30. Hajia, M, and Sohrabi, A (2018). Possible synergistic interactions among multiple HPV genotypes in women suffering from genital neoplasia. Asian Pac J Cancer Prev. 19, 785-9.
    Pubmed KoreaMed

June 2019, 24 (2)